ankylosing spondylitis

Fenbufen (Lederfen) is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Aceclofenac (Preservex) is a non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties.

Phenylbutazone (Butazolidine) is a butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ankylosing spondylitis, rheumatoid arthritis, and reactive arthritis.

Salazosulfamide has shown potential in the treatment of ankylosing spondylitis, according to research studies.

IL17A-IN-1 (Compound 72) is an orally active inhibitor of Interleukin 17A. This compound is applicable in research related to inflammatory and autoimmune diseases, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and cancer.

Azapropazone is anti-inflammatory agent. Azapropazone has uricosuric properties used to treat rheumatoid arthritis and ankylosing spondylitis. Azapropazone lowered plasma uric acid but exerted only a modest and variable uricosuric effect without altering

IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis[1].

SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).

(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is utilized in research on immune disorders [including rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus] and cancer.

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

Gumokimab (AK 111) is a humanized monoclonal antibody designed to specifically target interleukin-17A (IL-17A). it functions by competitively inhibiting the binding of IL-17A to its cognate receptor, thereby blocking downstream pro-inflammatory signaling, Gumokimab is a candidate for therapeutic research in psoriasis and ankylosing spondylitis.